Patricia L Winokur

List of Publications by Year
in descending order

77 papers	3,813 citations	172457 29 h-index	128289 60 g-index
77 all docs	77 docs citations	77 times ranked	4298 citing authors

#	Article	IF	Citations
1	Evidence for Transfer of CMY-2 AmpC Î²-Lactamase Plasmids between Escherichia coli and Salmonella Isolates from Food Animals and Humans. Antimicrobial Agents and Chemotherapy, 2001, 45, 2716-2722.	3.2	365
2	Variations in the Prevalence of Strains Expressing an Extendedâ€Spectrum Î²â€Lactamase Phenotype and Characterization of Isolates from Europe, the Americas, and the Western Pacific Region. Clinical Infectious Diseases, 2001, 32, S94-S103.	5.8	352
3	Animal and Human Multidrug-Resistant, Cephalosporin-Resistant Salmonella Isolates Expressing a Plasmid-Mediated CMY-2 AmpC Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2000, 44, 2777-2783.	3.2	265
4	Phylogenetic Origin and Virulence Genotype in Relation to Resistance to Fluoroquinolones and/or Extendedâ€Spectrum Cephalosporins and Cephamycins amongEscherichia coliIsolates from Animals and Humans. Journal of Infectious Diseases, 2003, 188, 759-768.	4.0	227
5	Antimicrobial Drugâ€"ResistantEscherichia colifrom Humans and Poultry Products, Minnesota and Wisconsin, 2002â€"2004. Emerging Infectious Diseases, 2007, 13, 838-846.	4.3	190
6	Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine, 2007, 25, 7656-7663.	3.8	151
7	Active choice but not too active: Public perspectives on biobank consent models. Genetics in Medicine, 2011, 13, 821-831.	2.4	127
8	Serological Responses to an Avian Influenza A/H7N9 Vaccine Mixed at the Point-of-Use With MF59 Adjuvant. JAMA - Journal of the American Medical Association, 2014, 312, 1409.	7.4	126
9	Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997. Diagnostic Microbiology and Infectious Disease, 1999, 35, 55-63.	1.8	120
10	Association between ceftiofur use and isolation ofEscherichia coliwith reduced susceptibility to ceftriaxone from fecal samples of dairy cows. American Journal of Veterinary Research, 2006, 67, 1696-1700.	0.6	105
11	A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine, 2010, 28, 2076-2079.	3.8	99
12	Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naÃ¯ve subjects. Vaccine, 2015, 33, 5225-5234.	3.8	92
13	Analysis of Nontypeable Haemophilus influenzae Phase-Variable Genes During Experimental Human Nasopharyngeal Colonization. Journal of Infectious Diseases, 2013, 208, 720-727.	4.0	70
14	Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. Lancet Infectious Diseases, The, 2017, 17, 1255-1265.	9.1	70
15	Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (FluzoneÂ®) administered by intradermal and intramuscular route in healthy adults. Vaccine, 2011, 29, 5666-5674.	3.8	63
16	Safety and immunogenicity of IMVAMUNEÂ® smallpox vaccine using different strategies for a post event scenario. Vaccine, 2013, 31, 3025-3033.	3.8	57
17	Vaccination Success Rate and Reaction Profile With Diluted and Undiluted Smallpox Vaccine. JAMA - Journal of the American Medical Association, 2004, 292, 1205.	7.4	53
18	Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine, 2009, 27, 5091-5095.	3.8	52

#	Article	IF	Citations
19	Strainâ€Relatedness of Methicillinâ€ResistantStaphylococcus aureusIsolates Recovered from Patients with Repeated Infection. Clinical Infectious Diseases, 2008, 46, 1241-1247.	5.8	51
20	Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine With MF59 Adjuvant. JAMA - Journal of the American Medical Association, 2014, 312, 1420.	7.4	45
21	First Description of Klebsiella pneumoniae Harboring CTX-M Î²-Lactamases (CTX-M-14 and CTX-M-3) in Taiwan. Antimicrobial Agents and Chemotherapy, 2002, 46, 1098-1100.	3.2	44
22	Impact of Body Mass Index on Immunogenicity of Pandemic H1N1 Vaccine in Children and Adults. Journal of Infectious Diseases, 2014, 210, 1270-1274.	4.0	43
23	Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f Î²-lactamase (SME-1) in the United States: results from the MYSTIC Programme. Diagnostic Microbiology and Infectious Disease, 2001, 39, 125-127.	1.8	37
24	Community-Associated Methicillin-ResistantStaphylococcus aureus, Iowa, USA. Emerging Infectious Diseases, 2009, 15, 1582-1589.	4.3	37
25	Cefepime MIC as a Predictor of the Extended-Spectrum Î²-Lactamase Type inKlebsiella pneumoniae,Taiwan. Emerging Infectious Diseases, 2002, 8, 522-524.	4.3	36
26	Immunogenicity and Safety of Varying Dosages of a Monovalent 2009 H1N1 Influenza Vaccine Given With and Without AS03 Adjuvant System in Healthy Adults and Older Persons. Journal of Infectious Diseases, 2012, 206, 811-820.	4.0	36
27	The Transactivation and DNA Binding Domains of the BPV-1 E2 Protein Have Different Roles in Cooperative Origin Binding with the E1 Protein. Virology, 1996, 221, 44-53.	2.4	35
28	Identification of Single Amino Acids in the Human Papillomavirus 11 E2 Protein Critical for the Transactivation or Replication Functions. Virology, 1998, 241, 312-322.	2.4	35
29	CD11a and CD49d enhance the detection of antigen-specific T cells following human vaccination. Vaccine, 2017, 35, 4255-4261.	3.8	33
30	Distinct gene expression profiles in peripheral blood mononuclear cells from patients infected with vaccinia virus, yellow fever 17D virus, or upper respiratory infections. Vaccine, 2007, 25, 6458-6473.	3.8	31
31	Tularemia vaccine: Safety, reactogenicity, â€œTakeâ€•skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain â€“ A phase 2 randomized clinical Trial. Vaccine, 2017, 35, 4730-4737.	3.8	30
32	Phase II randomized, double-blinded comparison of a single high dose (5Ã—108 TCID50) of modified vaccinia Ankara compared to a standard dose (1Ã—108 TCID50) in healthy vaccinia-naÃ¯ve individuals. Vaccine, 2014, 32, 2732-2739.	3.8	29
33	Increased Mortality Rates Associated withStaphylococcus aureusand Influenza Co-infection, Maryland and Iowa, USA1. Emerging Infectious Diseases, 2016, 22, 1253-1256.	4.3	29
34	Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Volunteers: a Randomized, Placebo-Controlled First-in-Human Single-Dose Escalation Study. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	29
35	Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine, 2008, 26, 4057-4061.	3.8	28
36	Predictors of Antimicrobialâ€ResistantEscherichia coliin the Feces of Vegetarians and Newly Hospitalized Adults in Minnesota and Wisconsin. Journal of Infectious Diseases, 2008, 197, 430-434.	4.0	28

#	Article	IF	Citations
37	Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules. Pediatrics, 2016, 137, e20152603.	2.1	28
38	Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine, 2012, 30, 4240-4248.	3.8	27
39	Confirmation of extended-spectrum Î²-lactamase-producing Serratia marcescens: preliminary report from Taiwan. Diagnostic Microbiology and Infectious Disease, 2003, 45, 221-224.	1.8	26
40	Higher Antigen Content Improves the Immune Response to 2009 H1N1 Influenza Vaccine in HIV-Infected Adults: A Randomized Clinical Trial. Journal of Infectious Diseases, 2012, 205, 703-712.	4.0	26
41	Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 214-224.	1.3	26
42	Molecular Characterization of the Î²-Lactamases from Clinical Isolates of Moraxella (Branhamella) catarrhalis Obtained from 24 U.S. Medical Centers during 1994â€“1995 and 1997â€“1998. Antimicrobial Agents and Chemotherapy, 2000, 44, 444-446.	3.2	25
43	BD Phoenix and Vitek 2 Detection of mecA -Mediated Resistance in Staphylococcus aureus with Cefoxitin. Journal of Clinical Microbiology, 2009, 47, 2879-2882.	3.9	25
44	Long-Term Risk for Readmission, Methicillin-Resistant Staphylococcus aureus (MRSA) Infection, and Death among MRSA-Colonized Veterans. Antimicrobial Agents and Chemotherapy, 2013, 57, 1169-1172.	3.2	22
45	Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: results from the SENTRY Antimicrobial Surveillance Program (1997). Clinical Microbiology and Infection, 1999, 5, 478-487.	6.0	20
46	Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women. Vaccine, 2018, 36, 8054-8061.	3.8	20
47	Development of a Prediction Rule for Methicillin-ResistantStaphylococcus aureusand Vancomycin-ResistantEnterococcusCarriage in a Veterans Affairs Medical Center Population. Infection Control and Hospital Epidemiology, 2008, 29, 969-971.	1.8	19
48	A randomized, placeboâ€controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with endâ€stage renal disease immunized prior to renal transplantation. Transplant Infectious Disease, 2018, 20, e12874.	1.7	19
49	Safety and Immunological Outcomes Following Human Inoculation With Nontypeable Haemophilus influenzae. Journal of Infectious Diseases, 2013, 208, 728-738.	4.0	18
50	Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. PLoS ONE, 2019, 14, e0222178.	2.5	18
51	Emergence of Two Klebsiella pneumoniae Isolates Harboring Plasmid-Mediated CTX-M-15 Î²-Lactamase in Taiwan. Antimicrobial Agents and Chemotherapy, 2004, 48, 362-363.	3.2	17
52	Reducing the Dose of Smallpox Vaccine Reduces Vaccineâ€Associated Morbidity without Reducing Vaccination Success Rates or Immune Responses. Journal of Infectious Diseases, 2007, 195, 826-832.	4.0	17
53	Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine, 2017, 35, 1675-1682.	3.8	17
54	Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open-Label Phase 1 Multiple Ascending Dose and Food Effect Study. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	17

#	Article	IF	Citations
55	Phenotypic and genotypic characterizations of chinese strains of Escherichia coli producing extended-spectrum Î²-lactamases. Diagnostic Microbiology and Infectious Disease, 1999, 34, 159-164.	1.8	15
56	Emergence of the USA300 Strain of Methicillin-Resistant Staphylococcus aureus in a Burn-Trauma Unit. Journal of Burn Care and Research, 2008, 29, 790-797.	0.4	15
57	Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74â€¯years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine, 2018, 36, 606-614.	3.8	14
58	Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	14
59	Development and validation of a simple, fast, and sensitive LC/MS/MS method for the quantification of oxfendazole in human plasma and its application to clinical pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2019, 171, 111-117.	2.8	14
60	Rapid, Culture-Free Detection of Staphylococcus aureus Bacteremia. PLoS ONE, 2016, 11, e0157234.	2.5	12
61	Characterization of extended spectrum Î²-lactamase-producing Klebsiella pneumoniae from Beijing, China. International Journal of Antimicrobial Agents, 2001, 18, 185-188.	2.5	11
62	Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial. Open Forum Infectious Diseases, 2014, 1, ofu102.	0.9	11
63	Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons â‰¥18 Years Old. Journal of Infectious Diseases, 2015, 212, 552-561.	4.0	11
64	Safety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine. Journal of Infectious Diseases, 2015, 212, 525-530.	4.0	11
65	Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 2: Stability Evaluation. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	11
66	Surveillance in Taiwan Using Molecular Epidemiology for Extended-Spectrum Beta-Lactamase-ProducingKlebsiella pneumoniae. Infection Control and Hospital Epidemiology, 2004, 25, 812-818.	1.8	10
67	High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: Results of the DMID 10-0076 randomized clinical trial. Vaccine, 2020, 38, 3934-3941.	3.8	10
68	Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses. Journal of Infectious Diseases, 2021, 224, 1372-1382.	4.0	10
69	Safety and Immune Responses in Children After Concurrent or Sequential 2009 H1N1 and 2009-2010 Seasonal Trivalent Influenza Vaccinations. Journal of Infectious Diseases, 2012, 206, 828-837.	4.0	8
70	Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination. Journal of Infectious Diseases, 2016, 214, 1020-1029.	4.0	6
71	Association between microbial characteristics and poor outcomes among patients with methicillin-resistant Staphylococcus aureus pneumonia: a retrospective cohort study. Antimicrobial Resistance and Infection Control, 2015, 4, 51.	4.1	5
72	Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	5

#	Article	IF	Citations
73	Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine. Vaccine, 2016, 34, 547-554.	3.8	4
74	Five Percent Monolaurin Vaginal Gel for the Treatment of Bacterial Vaginosis: A Randomized Placebo-Controlled Trial. Journal of Lower Genital Tract Disease, 2020, 24, 277-283.	1.9	4
75	Russian Klebsiella pneumoniae isolates that express extended-spectrum Î²-lactamases. Clinical Microbiology and Infection, 2000, 6, 103-108.	6.0	3
76	Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65Âyears and older. Vaccine, 2021, 39, 1339-1348.	3.8	2
77	Population Pharmacokinetic-Pharmacodynamic Model of Oxfendazole in Healthy Adults in a Multiple Ascending Dose and Food Effect Study and Target Attainment Analysis. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0143221.	3.2	0